These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Management of adverse effects related to human immunoglobulin therapy: Recommendations for clinical practice]. Marie I; Chérin P; Michallet M; Pelus E; Dantal J; Crave JC; Delain JC; Viallard JF Rev Med Interne; 2017 May; 38(5):312-319. PubMed ID: 27884454 [TBL] [Abstract][Full Text] [Related]
3. Adverse Effects of Immunoglobulin Therapy. Guo Y; Tian X; Wang X; Xiao Z Front Immunol; 2018; 9():1299. PubMed ID: 29951056 [TBL] [Abstract][Full Text] [Related]
4. Adverse effects of human immunoglobulin therapy. Stiehm ER Transfus Med Rev; 2013 Jul; 27(3):171-8. PubMed ID: 23835249 [TBL] [Abstract][Full Text] [Related]
5. Management of adverse events in the treatment of patients with immunoglobulin therapy: A review of evidence. Cherin P; Marie I; Michallet M; Pelus E; Dantal J; Crave JC; Delain JC; Viallard JF Autoimmun Rev; 2016 Jan; 15(1):71-81. PubMed ID: 26384525 [TBL] [Abstract][Full Text] [Related]
6. Adverse events associated with intravenous immunoglobulin therapy. Hamrock DJ Int Immunopharmacol; 2006 Apr; 6(4):535-42. PubMed ID: 16504916 [TBL] [Abstract][Full Text] [Related]
7. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Abbas A; Rajabally YA Curr Drug Saf; 2019; 14(1):3-13. PubMed ID: 30332974 [TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin Replacement Therapy for Primary Immunodeficiency. Sriaroon P; Ballow M Immunol Allergy Clin North Am; 2015 Nov; 35(4):713-30. PubMed ID: 26454315 [TBL] [Abstract][Full Text] [Related]
9. [The use of human immunoglobulins--adverse reactions]. Pituch-Noworolska A; Błaut-Szlósarczyk A; Zwonarz K Pol Merkur Lekarski; 2010 Sep; 29(171):202-5. PubMed ID: 20931833 [TBL] [Abstract][Full Text] [Related]
14. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. Quinti I; Soresina A; Agostini C; Spadaro G; Matucci A; Sfika I; Martini H; Borghese F; Guerra A; Alessandra V; Visentini M; Plebani A; Fiorilli M J Clin Immunol; 2008 May; 28(3):263-7. PubMed ID: 18214651 [TBL] [Abstract][Full Text] [Related]
15. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Rezaei N; Abolhassani H; Aghamohammadi A; Ochs HD Expert Rev Clin Immunol; 2011 May; 7(3):301-16. PubMed ID: 21595597 [TBL] [Abstract][Full Text] [Related]
16. Adverse reactions of prophylactic intravenous immunoglobulin infusions in Iranian patients with primary immunodeficiency. Aghamohammadi A; Farhoudi A; Nikzad M; Moin M; Pourpak Z; Rezaei N; Gharagozlou M; Movahedi M; Atarod L; Afshar AA; Bazargan N; Hosseinpoor AR Ann Allergy Asthma Immunol; 2004 Jan; 92(1):60-4. PubMed ID: 14756466 [TBL] [Abstract][Full Text] [Related]
17. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Eijkhout HW; van den Broek PJ; van der Meer JW Neth J Med; 2003 Jun; 61(6):213-7. PubMed ID: 12948165 [TBL] [Abstract][Full Text] [Related]
18. Adverse effects of intravenous immunoglobulin therapy. Nydegger UE; Sturzenegger M Drug Saf; 1999 Sep; 21(3):171-85. PubMed ID: 10487396 [TBL] [Abstract][Full Text] [Related]
19. Passive blood anaphylaxis: subcutaneous immunoglobulins are a cause of ongoing passive anaphylactic reaction. Zdziarski P; Gamian A; Majda J; Korzeniowska-Kowal A Allergy Asthma Clin Immunol; 2017; 13():41. PubMed ID: 28924447 [TBL] [Abstract][Full Text] [Related]
20. Safety of intravenous immunoglobulin in the treatment of juvenile dermatomyositis: adverse reactions are associated with immunoglobulin A content. Manlhiot C; Tyrrell PN; Liang L; Atkinson AR; Lau W; Feldman BM Pediatrics; 2008 Mar; 121(3):e626-30. PubMed ID: 18299304 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]